General Information of the Drug (ID: M6APDG03530)
Name
ISIS 101998
Status
Investigative
TTD Drug ID
D0X1NL
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
MADH6 messenger RNA (MADH6 mRNA)
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
Response Summary MADH6 messenger RNA (MADH6 mRNA) is a therapeutic target for ISIS 101998. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ISIS 101998 through regulating the expression of MADH6 messenger RNA (MADH6 mRNA). [1], [2]
References
Ref 1 RNA demethylase ALKBH5 inhibits TGF-Beta-induced EMT by regulating TGF-Beta/SMAD signaling in non-small cell lung?cancer. FASEB J. 2022 May;36(5):e22283. doi: 10.1096/fj.202200005RR.
Ref 2 Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature. Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. doi: 10.1080/13543776.2017.1360285. Epub 2017 Aug 2.